ERBB2 and breast carcinoma: In 2020, the FDA also approved Neratinib for use in combination with capecitabine as a treatment option for advanced or metastatic HER2-positive breast cancer patients who have received two or more prior anti-HER2-based regimens in the metastatic setting [35].